Health committee  Thank you.

Health committee  No. I would say the same. There are programs right now for prescribers when it comes to appropriate use and prescribing guidelines for the elderly, especially, as you said, when it comes to the number of drugs that are interfering with each other, and things like that. Other tha

Health committee  I would agree. The savings on generics have allowed us, just like the Swedes, to buffer the additional growth in the prices of specialty drugs, so we've had a relatively flat budget for pharmaceuticals. This has also allowed us to take up the more expensive products, for instance

Health committee  It's the same here. There is a normal fee that you pay, which everyone has to pay every month, but at the same time there is an income-related subsidy for those with lower incomes, so that the monthly premiums go down, but then there is still the copayment issue.

Health committee  For these patients or these people who are not able to pay that, there are special provisions. For instance, there are municipalities that are reinsuring the copayments for a very limited group. There are different mechanisms in place.

Health committee  I would agree.

Health committee  For the generics, especially, yes. It's to a limited extent when it comes to single-source products that are of equal benefit.

Health committee  Unfortunately, this is not really my expertise. So, unfortunately, it would be very difficult to explain what happened in 2006. I don't really have very specific lessons to hand over. I would definitely say that if you were to engage in such a system, you should make sure that y

Health committee  Traditionally we've had a system with relatively low copayments. This is our tradition. I believe some time ago there was an experiment with copayments specifically for drugs, but this was withdrawn after it was shown that many people were opposed to that, so in the new system, e

Health committee  Basically, if an insurance company is able to maintain low expenditures on pharmaceuticals, they can spend more of the premiums toward other forms of care.

Health committee  There were many challenges, we could say. I specialize a bit more in the pharmaceutical area, but in general you could say that one of the big challenges after 2006 has been for the different stakeholders to grow into their roles. For instance, insurance companies came from a non

Health committee  Yes, that's a very interesting question. Sometimes things evolve based on political decisions or motivations, so that might also have an effect. We came from a situation where there was more or less a clear distinction between the insurance companies. They were more regionall

Health committee  What do you mean exactly by the different classes?

Health committee  Do you mean the clustering of the products?

Health committee  Okay. By having clusters of products that have equal benefit, with the health technology assessment showing that there is equal therapeutic benefit between, for instance, two active substances, the person will receive the maximum reimbursement in this cluster. The prescriber has